Periprocedural Infarction vs. Spontaneous Infarction: Prognostic Significance 

Original title: Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction. Reference: Sergio Leonardi, MD et al. Journal of the American College of Cardiology Vol. 60, No. 22, 2012

Clinical significance of myocardial infarction (MI) associated to coronary angioplasty is a controversial issue worldwide. Most of research on coronary disease includes it as a primary end point weighed against spontaneous MI.

The aim of this study was to compare periprocedural MI vs. spontaneous MI. It analyzed data from 9,087 patients enrolled in two trials that assessed Non ST Segment Elevation Acute Coronary Syndrome (EARLY-ACS and SYNERGY): among these, 893 periprocedural MI and 298 spontaneous MI occurred, and ratios for death at 12 months were compared.

Authors defined periprocedural MI as CK-MB more than 3 times the ULN (upper limit of normal). Adjusted hazard ratios for 1-year death were 1.39 (95% CI: 1.01 to 1.89) for periprocedural MI vs. 5.37 (95% CI: 3.9 to 7.38) for spontaneous MI. In determining the CK-Mb threshold for periprocedural MI to achieve the same prognosis as spontaneous MI, it was observed that elevations of 27 times the ULN were necessary for this to happen.

Conclusion 

The definition of periprocedural infarction used in clinical trials is poorly associated to events, compared to spontaneous infarction.

Editorial Comment:

This study confirms an assumption based on intuition, that cardiac enzymes elevation after angioplasty does not have the same prognosis than Type 1 MI. Further evaluation is required to confirm these results using the new definition of periprocedural MI (a 5 times increase of troponin levels with clinical or electrical signs or ischemia image). Despite the above observations, this study is good news for interventional cardiologists.

Courtesy of María Sol Andres, MD
Hospital Universitario
Fundación Favaloro – Argentina

Dra. María Sol Andrés para SOLACI.ORG

More articles by this author

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...